V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Zentalis Pharmaceuticals Executive Compensation (FY25)

ZNTL · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Julie Eastland
Latest say-on-pay support
=
June 16, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Zentalis Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 18, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Zentalis Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
235 figures on this page: 230 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Julie Eastland: $8,188,909 → $1,300,731 (84.1% lower)
Say-on-pay support: 62.9% → 66.8% (3.9 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Zentalis Pharmaceuticals' chief executive and what were they paid?
Julie Eastland, President and Chief Executive Officer, received $1,300,731 in total compensation for fiscal 2025. Eastland's total moved 84.1% lower from the $8,188,909 reported for fiscal 2024.
What was Zentalis Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 66.8% of votes cast for or against in favor at the meeting held June 16, 2026.
Which companies are in Zentalis Pharmaceuticals' peer group?
The disclosed peer group includes Allogene Therapeutics, Inc., Arcus Biosciences, Inc., ARVINAS, Inc., Beam Therapeutics, Inc. and C4 Therapeutics, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kimberly Blackwell
Chief Executive Officer
◇◇—◇◇—◇◇
Cam Gallagher
President
◇—◇◇◇—◇◇
Anthony Sun
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Carrie Brownstein
Chief Medical Officer
◇—◇◇◇—◇◇
Andrea Paul
General Counsel and Corporate Secretary
◇——◇◇—◇◇
Kevin Bunker
Chief Scientific Officer
◇—◇◇◇—◇◇
Melissa Epperly
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kimberly Blackwell
Former Chief Executive Officer and Interim Chief Medical Officer
◇—◇◇◇—◇◇
Cam Gallagher
Former President, Interim Chief Financial Officer and Interim Treasurer
Served on an interim basis
◇—◇◇◇—◇◇
Iris Roth
Former Chief Operating Officer
Departed during or after this year
◇—◇◇◇—◇◇
Melissa Epperly
Former Chief Financial Officer and Treasurer
Departed during or after this year
◇—◇◇◇—◇◇
Kevin Bunker
Former Chief Scientific Officer
Departed during or after this year
◇—◇◇——◇◇
Andrea Paul
Chief Legal Officer and Corporate Secretary
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Julie Eastland
President and Chief Executive Officer
◇◇—◇◇—◇◇
Kimberly Blackwell
Former Chief Executive Officer and Interim Chief Medical Officer
Departed during or after this year
◇—◇◇——◇◇
Diana Hausman
Former Chief Medical Officer
Departed during or after this year
◇◇◇◇——◇◇
Cam Gallagher
Former President, Interim Chief Financial Officer and Interim Treasurer
Departed during or after this year
◇—◇◇——◇◇
Mark Lackner
Former Chief Scientific Officer
◇—◇◇◇—◇◇
Andrea Paul
Former Chief Legal Officer and Corporate Secretary
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrea Paul
Former Chief Legal Officer and Corporate Secretary
Departed during or after this year
◇—◇◇——◇◇
Julie Eastland
President and Chief Executive Officer
◇—◇◇◇—◇◇
Mark Lackner
Former Chief Scientific Officer
Departed during or after this year
◇—◇◇——◇◇
Ingmar Bruns
Chief Medical Officer
◇—◇◇◇—◇◇
James Bucher
Chief Legal Officer and Corporate Secretary
◇◇—◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrea PaulOTHER——————◇
Ingmar BrunsOTHER——————◇
Julie EastlandOTHER——————◇
Mark LacknerOTHER——————◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Andrea PaulOption◇—◇2/2/2035
Option◇—◇7/31/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2034
Option◇—◇1/31/2034
Option◇—◇1/31/2033
Mark LacknerOption◇—◇2/2/2035
Option◇—◇1/31/2034
Option◇—◇10/31/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2033
Option◇—◇1/1/2034
Ingmar BrunsRSU◇◇——
Option◇—◇2/2/2035
Option◇—◇12/1/2034
James BucherOption◇—◇9/30/2035
Julie EastlandRSU◇◇——
Option◇—◇2/2/2035
Option◇—◇12/1/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Andrea Paul
Former Chief Legal Officer and Corporate Secretary · Severance agreement · citing a 2025 filing
Severance cash amount◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Scott Myers
◇◇————◇
Jan Skvarka, Ph.D
◇◇————◇
Enoch Kariuki, Pharm.D
◇◇————◇
Luke Walker, M.D
◇◇————◇
David Johnson
◇◇————◇
Karan Takhar and Julie Eastland served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
  • Allogene Therapeutics, Inc. ALLO
  • Arcus Biosciences, Inc. RCUS
  • ARVINAS, Inc. ARVN
  • Beam Therapeutics, Inc. BEAM
  • C4 Therapeutics, Inc. CCCC
  • Celldex Therapeutics, Inc. CLDX
  • CRISPR Therapeutics AG CRSP
  • Cytokinetics Inc. CYTK
  • Day One Biopharmaceuticals, Inc. DAWN
  • Denali Therapeutics Inc. DNLI
  • Erasca, Inc. ERAS
  • Fate Therapeutics Inc. FATE
  • ImmunoGen, Inc. IMGN
  • Kura Oncology, Inc. KURA
  • Kymera Therapeutics, Inc. KYMR
  • Lyell Immunopharma, Inc. LYEL
  • Mirati Therapeutics, Inc. MRTX
  • Nektar Therapeutics NKTR
  • Relay Therapeutics, Inc. RLAY
  • Sana Biotechnology, Inc. SANA
  • Springworks Therapeutics, Inc. SWTX
  • TG Therapeutics, Inc. TGTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 16, 2026=◇◇◇
2024June 17, 2025=◇◇◇
2023June 21, 2024=◇◇◇
2022June 16, 2023=◇◇◇
2021June 8, 2022=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Julie Eastland (President and Chief Executive Officer), FY2025 total compensation $1,300,731 (base salary $700,000) [exec_comp, SEC accession 0001725160-26-000027, filed 2026-04-30]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Zentalis Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Zentalis Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Zentalis Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Zentalis Pharmaceuticals recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Zentalis Pharmaceuticals' disclosed peer group is defensible, who names Zentalis Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
235 figures on this page: 230 cited to the filing that reported them, 5 calculated from figures it prints.
230 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001725160-26-000052
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001725160-26-000027
    2025 Summary Compensation Table · DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION
  3. 0001725160-25-000127
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001725160-25-000092
  5. 0001725160-24-000140
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001725160-24-000096
    EXECUTIVE COMPENSATION TABLES
  7. 0001725160-23-000148
  8. 0001725160-23-000078
    EXECUTIVE COMPENSATION TABLES
  9. 0001725160-22-000123
  10. 0001725160-25-000161
    EX-10.13
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Zentalis Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ZNTL (accessed 2026).
Short form: data: Velarion

The Zentalis Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Zentalis Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Zentalis Pharmaceuticals discloses

The companies named in ZNTL's own disclosed peer group.

Allogene Therapeutics, Inc.Arcus Biosciences, Inc.ARVINAS, Inc.Beam Therapeutics, Inc.C4 Therapeutics, Inc.Celldex Therapeutics, Inc.CRISPR Therapeutics AGCytokinetics Inc.Day One Biopharmaceuticals, Inc.Denali Therapeutics Inc.Erasca, Inc.Fate Therapeutics Inc.ImmunoGen, Inc.Kura Oncology, Inc.Kymera Therapeutics, Inc.Lyell Immunopharma, Inc.Mirati Therapeutics, Inc.Nektar TherapeuticsRelay Therapeutics, Inc.Sana Biotechnology, Inc.Springworks Therapeutics, Inc.TG Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy